Investors Urged to Join Class Action Against Savara Inc. Following Misleading Information

Legal Action Against Savara Inc.: What You Need to Know

In a recent development, Robbins LLP announced a class action lawsuit aimed at seeking justice for shareholders who invested in Savara Inc. (NASDAQ: SVRA) during the period from March 7, 2024, to May 23, 2025. The lawsuit stems from allegations that the biopharmaceutical company misled investors regarding the potential success of its lead drug candidate, MOLBREEVI (molgramostim).

Savara, which focuses on therapies for rare respiratory diseases, found itself in the crosshairs of scrutiny when the U.S. Food and Drug Administration (FDA) issued a refusal to file (RTF) letter regarding its Biologics License Application (BLA) for MOLBREEVI. This shock announcement was released on May 27, 2025, and revealed critical failures in the submission regarding the drug’s chemistry, manufacturing, and controls.

Allegations of Misleading Information

According to the complaint, Savara's management allegedly failed to inform shareholders that the BLA lacked essential details, which significantly undermined the likelihood of FDA approval in its current state. This oversight had broader implications, suggesting that the company might not meet its previously communicated timelines for the drug's review and possibly necessitating additional funding to support continued operations.

As a consequence of the negative information made public, Savara's stock plummeted by 31.69%, closing at $1.94 per share on the day of the announcement. This decline meant significant financial losses for shareholders who had invested in the company, believing they were part of a promising venture.

Next Steps for Shareholders

Shareholders who believe they suffered losses due to these misleading statements are encouraged to take action. Those interested in serving as a lead plaintiff within the class action must submit their documents to the court by November 7, 2025. The lead plaintiff serves a vital role in guiding the litigation process and can represent the interests of other affected shareholders.

Robbins LLP operates on a contingency fee basis, meaning that shareholders will not incur legal fees unless there is a settlement or favorable outcome. This provides some assurance to investors who may be hesitant to engage in litigation due to financial concerns.

About Robbins LLP

Since its inception in 2002, Robbins LLP has been at the forefront of shareholder rights litigation, committed to recovering losses incurred by investors while ensuring transparency and accountability within corporate governance. With a strong track record, Robbins LLP has established itself as a reliable partner for aggrieved investors seeking justice.

For more information on how to participate in the class action or to stay updated on the proceedings, interested parties can contact Robbins LLP directly. The firm is dedicated to keeping shareholders informed about developments regarding their investments and any potential recoveries that may arise from the lawsuit.

If you have lost money investing in Savara, don’t remain in the dark. Immediate action is critical—reach out to Robbins LLP to find out more about your rights and options. Their expertise could prove essential in navigating this complex situation and seeking the justice you deserve.